Cancer-Associated Thrombosis: A Critical Gap in Cancer Care

“Cancer-associated thrombosis (CAT) is one of the most common yet preventable causes of death among cancer patients. With over 20,000 Canadians being diagnosed with cancer each year, knowing about causes, prevention, and treatment of CAT will be critical to the quality of life and long-term survival of these individuals. CAT refers to blood clots that can

Registration Now Open for the Second Annual Drug Pricing Policy Summit

On November 15-16, 2017 from 8:30 a.m. – 5:00 p.m., you are invited to join the Save Your Skin Foundation, the Canadian Cancer Survivor Network and the Schizophrenia Society of Ontario and other patient groups for the second annual Drug Pricing Policy Summit – Measuring Progress and Making Our Mark. This year’s Summit will build

Saskatchewan latest province to help protect boys from cancer with HPV vaccine

Grade 6 boys in Saskatchewan will now receive a vaccine to prevent some types of cancer. Starting this year 7,500 boys will be eligible to receive the human papillomavirus, or HPV, vaccine. “If you knew you could prevent cancer and your son or daughter develops that cancer, and they still might, but if you had

pCODR gives initial positive recommendation for Ovarian Cancer Drug

pCODR recently announced their initial positive recommendation for Olaparib (Lynparza), a targeted therapy for ovarian cancer. As part of their recommendation, pCODR stated that “Reimbursement should be for olaparib monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic as detected by approved testing) high grade serious epithelial ovarian, fallopian tube, or

Do You have Metastatic Prostate Cancer?

Bayer is conducting a research study in men with metastatic hormone-sensitive prostate cancer. The purpose of this study is to find out if the study drug is safe and effective at keeping prostate cancer under control or slowing the growth of tumors when given in addition to androgen deprivation therapy (ADT) and docetaxel chemotherapy. To

Western Day 2017 Adapting to Survive: Innovation in Reimbursement in Western Canada

On Tuesday, September 12, 2017, the Canadian Association for Healthcare Reimbursement will host an event featuring some of the leaders in the Canadian Health industry. With a variety of panel discussions planned, the day will be extremely informative to all in attendance. To see a copy of the event brochure including a list of speakers,

2017 National Lymphedema Conference

Montreal • October 27-28 A bilingual conference co-hosted by the Canadian Lymphedema Framework and the Lymphedema Association of Québec in collaboration with the McGill University Health Centre and Concordia University. Presenting key topics related to CHRONIC EDEMA and LYMPHEDEMA: Obesity, Lipedema, Pediatrics, Self-Management, Exercise, Compression, Measurement, Skin Care, Surgery, Wound Care, Psychosocial and Clinical Services.

CIHR – ICR Late Breaking Funding Opportunity

ICR is pleased to announce a Recent Partnership with AstraZeneca (AZ) to develop the independence of New Investigators in initiating and conducting research in the area of metastatic bladder cancer. This partnership will provide funding for one award, for an Early Career Investigator to support research in the area of locally advanced or metastatic bladder

Connect with us on LinkedIn!

Are you on LinkedIn? If so, we’d love to connect with you! Visit our profile at https://ca.linkedin.com/company/canadian-cancer-survivor-network and be sure to follow us!